MD · Pediatrix Medical Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $60.27M | - | $60.79M | $55.71M | $58.60M | - | $58.12M | $56.56M | $60.20M | - |
| Total Operating Expenses | $434.54M | - | $424.82M | $408.98M | $426.26M | - | $477.33M | $662.02M | $479.21M | - |
| D&A | $6.12M | - | $5.55M | $5.31M | $5.33M | - | $6.25M | $8.79M | $10.31M | - |
| Operating Income | $41.66M | - | $68.05M | $59.87M | $32.10M | - | $33.83M | ($157.72M) | $15.89M | - |
| Interest Expense | $8.27M | - | $8.94M | $10.31M | $10.60M | - | $10.13M | $10.31M | $10.60M | - |
| Income Tax | $9.27M | - | $16.07M | $15.71M | $7.35M | - | $5.79M | ($14.70M) | $3.79M | - |
| Net Income | $29.57M | - | $71.71M | $39.26M | $20.74M | - | $19.44M | ($153.03M) | $4.04M | - |
| EPS - Basic | $0.37 | - | $0.85 | $0.46 | $0.25 | - | $0.23 | ($1.84) | $0.05 | - |
| EPS - Diluted | $0.36 | - | $0.84 | $0.46 | $0.24 | - | $0.23 | ($1.84) | $0.05 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $205.78M | $375.24M | $340.06M | $224.73M | $98.98M | $229.94M | $103.83M | $19.40M | $8.00M | $73.26M |
| Accounts Receivable | $224.80M | $229.66M | $231.12M | $238.99M | $242.53M | $259.99M | $286.90M | $274.16M | $283.75M | $272.31M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $31.54M | $37.22M | $38.65M | $42.06M | $44.12M | $46.43M | $47.37M | $32.00M | $31.64M | $34.59M |
| Current Assets | $587.03M | $763.51M | $717.20M | $613.05M | $491.67M | $639.61M | $528.22M | $429.21M | $426.52M | $483.45M |
| Total Assets | $2.07B | $2.25B | $2.20B | $2.10B | $1.99B | $2.15B | $2.08B | $2.00B | $2.17B | $2.22B |
| Current Liabilities | $442.64M | $458.91M | $392.55M | $341.04M | $271.05M | $434.11M | $373.08M | $310.16M | $247.28M | $388.95M |
| Long-term Debt | - | - | - | - | - | $611.20M | - | - | - | $622.20M |
| Total Liabilities | $1.19B | $1.38B | $1.31B | $1.27B | $1.20B | $1.39B | $1.34B | $1.29B | $1.31B | $1.37B |
| Stockholders' Equity | $878.58M | $865.85M | $890.67M | $833.75M | $789.19M | $764.94M | $732.49M | $706.46M | $856.20M | $849.06M |
| Retained Earnings | ($53.58M) | ($83.15M) | ($116.83M) | ($188.54M) | ($227.80M) | ($248.54M) | ($279.02M) | ($298.46M) | ($145.44M) | $149.47M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($129.85M) | - | - | - | ($117.46M) | - | - | - | ($125.23M) | - |
| Investing Cash Flow | ($11.98M) | - | - | - | ($7.46M) | - | - | - | ($16.24M) | - |
| Financing Cash Flow | ($27.64M) | - | - | - | ($6.04M) | - | - | - | $76.20M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 23.9% | - | 18.3% | 28.6% | 26.2% | - | 23.0% | - | 48.4% | - |
| Return on assets | 1.4% | - | 3.3% | 1.9% | 1.0% | - | 0.9% | -7.7% | 0.2% | - |
| Return on equity | 3.4% | - | 8.1% | 4.7% | 2.6% | - | 2.7% | -21.7% | 0.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.33 | 1.66 | 1.83 | 1.80 | 1.81 | 1.47 | 1.42 | 1.38 | 1.72 | 1.24 |
| Quick ratio | 1.33 | 1.66 | 1.83 | 1.80 | 1.81 | 1.47 | 1.42 | 1.38 | 1.72 | 1.24 |
| Cash ratio | 0.46 | 0.82 | 0.87 | 0.66 | 0.37 | 0.53 | 0.28 | 0.06 | 0.03 | 0.19 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.80 | - | - | - | 0.73 |
| Debt / Assets | - | - | - | - | - | 0.28 | - | - | - | 0.28 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 5.0x | - | 7.6x | 5.8x | 3.0x | - | 3.3x | -15.3x | 1.5x | - |
| Equity multiplier | 2.36 | 2.59 | 2.47 | 2.52 | 2.53 | 2.81 | 2.84 | 2.82 | 2.53 | 2.61 |
| Liabilities / Assets | 0.58 | 0.61 | 0.60 | 0.60 | 0.60 | 0.64 | 0.65 | 0.65 | 0.61 | 0.62 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 59.4x | - | 19.9x | 31.2x | 60.4x | - | 50.4x | - | 200.6x | - |
| P / B | 2.0x | - | 1.6x | 1.5x | 1.6x | - | 1.3x | 0.9x | 1.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | 32.9x | - | 14.9x | 15.4x | 30.4x | - | 21.9x | - | 31.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 29.8% | - | 101.2% | - | 102.0% | - | -16.0% | - | -47.1% | - |
| Net income growth (YoY) | 42.6% | - | 268.8% | - | 413.9% | - | -9.1% | - | -71.6% | - |
| EPS growth (YoY) | 50.0% | - | 265.2% | - | 380.0% | - | -11.5% | - | -70.6% | - |
| EPS CAGR (3y) | 28.4% | - | 31.4% | 12.9% | - | - | -13.9% | - | -38.0% | - |
| EPS CAGR (5y) | 11.4% | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 11.3% | 13.2% | 21.6% | 18.0% | -7.8% | -9.9% | -24.3% | -25.0% | -5.9% | -4.8% |
Peer comparison
Same SIC group: Services-Hospitals
Comparing Pediatrix Medical Group against the 3 most active filers in the same SIC group.